Concepts (121)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pharmacy Service, Hospital | 2 | 2026 | 21 | 1.020 |
Why?
|
| Omalizumab | 1 | 2026 | 1 | 0.950 |
Why?
|
| Anti-Allergic Agents | 1 | 2026 | 4 | 0.940 |
Why?
|
| Pharmacists | 3 | 2026 | 131 | 0.940 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2026 | 34 | 0.940 |
Why?
|
| Food Hypersensitivity | 1 | 2026 | 26 | 0.920 |
Why?
|
| Drug Industry | 1 | 2026 | 41 | 0.920 |
Why?
|
| Pyridones | 2 | 2017 | 42 | 0.890 |
Why?
|
| Interprofessional Relations | 1 | 2026 | 137 | 0.870 |
Why?
|
| Critical Illness | 5 | 2016 | 340 | 0.840 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 2 | 2017 | 162 | 0.780 |
Why?
|
| Hypnotics and Sedatives | 4 | 2016 | 66 | 0.770 |
Why?
|
| Analgesics | 2 | 2016 | 102 | 0.660 |
Why?
|
| Liver Diseases | 2 | 2016 | 157 | 0.630 |
Why?
|
| Pregnenediones | 1 | 2020 | 3 | 0.630 |
Why?
|
| Kidney Diseases | 2 | 2016 | 178 | 0.620 |
Why?
|
| Muscular Dystrophy, Duchenne | 1 | 2020 | 46 | 0.580 |
Why?
|
| Glucocorticoids | 1 | 2020 | 190 | 0.550 |
Why?
|
| Indoles | 1 | 2017 | 112 | 0.510 |
Why?
|
| Dabigatran | 1 | 2016 | 20 | 0.480 |
Why?
|
| Antithrombins | 1 | 2016 | 16 | 0.480 |
Why?
|
| Blood Coagulation | 1 | 2016 | 41 | 0.470 |
Why?
|
| Hemorrhage | 1 | 2016 | 286 | 0.420 |
Why?
|
| Nutrition Therapy | 1 | 2014 | 9 | 0.420 |
Why?
|
| Parenteral Nutrition | 1 | 2014 | 20 | 0.410 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2016 | 253 | 0.410 |
Why?
|
| Critical Care | 5 | 2016 | 416 | 0.350 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 202 | 0.340 |
Why?
|
| Liver Failure | 1 | 2010 | 18 | 0.320 |
Why?
|
| Pharmaceutical Vehicles | 1 | 2008 | 6 | 0.280 |
Why?
|
| Propylene Glycol | 1 | 2008 | 3 | 0.280 |
Why?
|
| Acidosis, Lactic | 1 | 2008 | 11 | 0.280 |
Why?
|
| Humans | 17 | 2026 | 65635 | 0.240 |
Why?
|
| Desensitization, Immunologic | 1 | 2026 | 13 | 0.230 |
Why?
|
| Conflict of Interest | 1 | 2026 | 38 | 0.230 |
Why?
|
| Professional Role | 1 | 2026 | 45 | 0.230 |
Why?
|
| Anaphylaxis | 1 | 2026 | 41 | 0.230 |
Why?
|
| Immunoglobulin E | 1 | 2026 | 81 | 0.230 |
Why?
|
| Antithrombin III | 1 | 2004 | 15 | 0.220 |
Why?
|
| Enoxaparin | 1 | 2004 | 19 | 0.220 |
Why?
|
| Burns | 1 | 2004 | 46 | 0.210 |
Why?
|
| Venous Thrombosis | 1 | 2004 | 113 | 0.200 |
Why?
|
| Liver Function Tests | 2 | 2016 | 38 | 0.180 |
Why?
|
| Kidney Function Tests | 2 | 2016 | 36 | 0.180 |
Why?
|
| Drug Monitoring | 2 | 2016 | 203 | 0.160 |
Why?
|
| Medical Order Entry Systems | 1 | 2020 | 42 | 0.150 |
Why?
|
| Electronic Mail | 1 | 2020 | 46 | 0.150 |
Why?
|
| Reminder Systems | 1 | 2020 | 75 | 0.150 |
Why?
|
| Treatment Outcome | 3 | 2020 | 5818 | 0.150 |
Why?
|
| Anticoagulants | 2 | 2020 | 529 | 0.140 |
Why?
|
| Continuity of Patient Care | 1 | 2020 | 175 | 0.140 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 154 | 0.130 |
Why?
|
| Cardiomyopathies | 1 | 2020 | 137 | 0.130 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 196 | 0.130 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2017 | 27 | 0.130 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2017 | 49 | 0.130 |
Why?
|
| Diarrhea | 1 | 2017 | 73 | 0.130 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 463 | 0.120 |
Why?
|
| Electronic Health Records | 1 | 2020 | 398 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 198 | 0.120 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 489 | 0.120 |
Why?
|
| Child | 1 | 2026 | 4633 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 808 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 710 | 0.110 |
Why?
|
| Carnitine | 1 | 2014 | 19 | 0.100 |
Why?
|
| Selenium | 1 | 2014 | 27 | 0.100 |
Why?
|
| Critical Care Nursing | 1 | 2014 | 24 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 462 | 0.100 |
Why?
|
| Quality of Life | 1 | 2020 | 1264 | 0.090 |
Why?
|
| Pharmacokinetics | 1 | 2012 | 7 | 0.090 |
Why?
|
| Hospitalization | 1 | 2020 | 1403 | 0.090 |
Why?
|
| Lipids | 1 | 2014 | 330 | 0.090 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 1163 | 0.080 |
Why?
|
| Atrial Fibrillation | 1 | 2020 | 884 | 0.080 |
Why?
|
| Stroke | 1 | 2020 | 1220 | 0.080 |
Why?
|
| Metabolic Clearance Rate | 2 | 2012 | 48 | 0.080 |
Why?
|
| Intestinal Absorption | 2 | 2012 | 32 | 0.080 |
Why?
|
| Insulin | 1 | 2014 | 696 | 0.080 |
Why?
|
| Sepsis | 1 | 2014 | 302 | 0.080 |
Why?
|
| Anesthetics, Intravenous | 1 | 2009 | 25 | 0.080 |
Why?
|
| Propofol | 1 | 2009 | 21 | 0.080 |
Why?
|
| Intensive Care Units | 2 | 2010 | 436 | 0.070 |
Why?
|
| Biological Availability | 2 | 2012 | 210 | 0.070 |
Why?
|
| Pentobarbital | 1 | 2008 | 4 | 0.070 |
Why?
|
| Status Epilepticus | 1 | 2008 | 24 | 0.070 |
Why?
|
| Infusions, Intravenous | 1 | 2008 | 193 | 0.070 |
Why?
|
| Nursing Assessment | 1 | 2005 | 46 | 0.060 |
Why?
|
| Half-Life | 1 | 2005 | 81 | 0.060 |
Why?
|
| Blood Flow Velocity | 1 | 2005 | 74 | 0.060 |
Why?
|
| Incidence | 1 | 2009 | 1432 | 0.060 |
Why?
|
| Tissue Distribution | 1 | 2005 | 292 | 0.050 |
Why?
|
| Telemedicine | 1 | 2010 | 376 | 0.050 |
Why?
|
| Female | 6 | 2020 | 34298 | 0.050 |
Why?
|
| Middle Aged | 4 | 2020 | 18434 | 0.040 |
Why?
|
| Male | 5 | 2020 | 31285 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2020 | 371 | 0.040 |
Why?
|
| Home Care Services | 1 | 2020 | 105 | 0.040 |
Why?
|
| Drug Utilization | 1 | 2020 | 204 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 170 | 0.040 |
Why?
|
| Adult | 3 | 2020 | 17508 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2020 | 318 | 0.030 |
Why?
|
| Patient Selection | 1 | 2020 | 484 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2020 | 521 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 631 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 770 | 0.030 |
Why?
|
| Massachusetts | 1 | 2020 | 2154 | 0.030 |
Why?
|
| Time Factors | 1 | 2020 | 3777 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2012 | 142 | 0.020 |
Why?
|
| Acute Kidney Injury | 1 | 2012 | 142 | 0.020 |
Why?
|
| Risk Factors | 1 | 2020 | 5466 | 0.020 |
Why?
|
| Syndrome | 1 | 2009 | 180 | 0.020 |
Why?
|
| Aged | 2 | 2020 | 15087 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2009 | 162 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2009 | 309 | 0.020 |
Why?
|
| Protein Binding | 1 | 2012 | 1633 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2010 | 310 | 0.020 |
Why?
|
| Liver | 1 | 2012 | 874 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2010 | 300 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 741 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2009 | 3328 | 0.010 |
Why?
|
| Heart Failure | 1 | 2009 | 965 | 0.010 |
Why?
|